PMID- 37509282
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230731
IS  - 2072-6694 (Print)
IS  - 2072-6694 (Electronic)
IS  - 2072-6694 (Linking)
VI  - 15
IP  - 14
DP  - 2023 Jul 14
TI  - Sonidegib in Locally Advanced Basal Cell Carcinoma: A Monocentric Retrospective 
      Experience and a Review of Published Real-Life Data.
LID - 10.3390/cancers15143621 [doi]
LID - 3621
AB  - Basal cell carcinoma (BCC) represents the most common skin cancer and locally 
      advanced BCC (laBCC) refers to an aggressive, large, infiltrative BCC that cannot 
      be treated by surgery or radiotherapy. Sonidegib is a Hedghehog inhibitor (HHi) 
      indicated for laBCC. This is a monocentric retrospective real-life study of 
      laBCCs receiving Sonidegib treatment. Although Sonidegib is widely used, since 
      its approval by Food and Drug Administration in 2015, only a limited number of 
      real-life experiences have been reported. Eleven patients, including four 
      patients diagnosed with Basal Cell Naevus syndrome, received treatment with 
      Sonidegib for laBCCs. Seven (63.6%) patients experienced adverse events (AEs) but 
      only three had to discontinue treatment and were therefore excluded from the 
      following results. Four patients (50%) achieved complete clinical remission (CR); 
      in all cases the remission was confirmed by biopsy. Partial response (PR) was 
      found in three patients out of eight (37.5%). One patient out of eight (12.5%) 
      showed a steady disease (SD). None of the patients showed signs of progression 
      during treatment with HHi. Sonidegib showed the same efficacy in treating laBCCs 
      as already seen in trials. All four patients suffering from Basal Cell Naevus 
      syndrome achieved disease control by being treated with Sonidegib. Consequently, 
      we strongly advise the joint management of laBCCs through a multidisciplinary 
      team whenever feasible.
FAU - Nazzaro, Gianluca
AU  - Nazzaro G
AUID- ORCID: 0000-0001-8534-6497
AD  - Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 
      20122 Milan, Italy.
FAU - Benzecry, Valentina
AU  - Benzecry V
AD  - Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 
      20122 Milan, Italy.
FAU - Mattioli, Maria A
AU  - Mattioli MA
AUID- ORCID: 0000-0001-6532-5066
AD  - Department of Physiopathology and Transplantation, University of Milan, 20122 
      Milan, Italy.
FAU - Denaro, Nerina
AU  - Denaro N
AUID- ORCID: 0000-0002-8605-4290
AD  - Oncology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 
      Milan, Italy.
FAU - Beltramini, Giada A
AU  - Beltramini GA
AD  - Maxillofacial Surgery and Odontostomatology Unit, Fondazione IRCCS Ca' Granda 
      Ospedale Maggiore Policlinico, 20122 Milan, Italy.
AD  - Department of Biomedical, Surgical and Dental Sciences, University of Milan, 
      20122 Milan, Italy.
FAU - Marzano, Angelo V
AU  - Marzano AV
AUID- ORCID: 0000-0002-8160-4169
AD  - Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 
      20122 Milan, Italy.
AD  - Department of Physiopathology and Transplantation, University of Milan, 20122 
      Milan, Italy.
FAU - Passoni, Emanuela
AU  - Passoni E
AD  - Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 
      20122 Milan, Italy.
LA  - eng
PT  - Journal Article
DEP - 20230714
PL  - Switzerland
TA  - Cancers (Basel)
JT  - Cancers
JID - 101526829
PMC - PMC10377077
OTO - NOTNLM
OT  - Hedgehog inhibitor
OT  - basal cell carcinoma
OT  - locally advanced basal cell carcinoma
OT  - real-life
OT  - sonidegib
COIS- The authors declare no conflict of interest.
EDAT- 2023/07/29 11:53
MHDA- 2023/07/29 11:54
PMCR- 2023/07/14
CRDT- 2023/07/29 01:11
PHST- 2023/06/21 00:00 [received]
PHST- 2023/07/11 00:00 [revised]
PHST- 2023/07/12 00:00 [accepted]
PHST- 2023/07/29 11:54 [medline]
PHST- 2023/07/29 11:53 [pubmed]
PHST- 2023/07/29 01:11 [entrez]
PHST- 2023/07/14 00:00 [pmc-release]
AID - cancers15143621 [pii]
AID - cancers-15-03621 [pii]
AID - 10.3390/cancers15143621 [doi]
PST - epublish
SO  - Cancers (Basel). 2023 Jul 14;15(14):3621. doi: 10.3390/cancers15143621.